CD19/CD20 CAR T-cells
/ PersonGen Biomedicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 07, 2021
CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology
1 to 1
Of
1
Go to page
1